APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist.
ORLANDO—Results from an international phase III trial in advanced non-small-cell lung cancer could change the standard of care, according to the lead investigator.
Oncology News International readers expressed doubts about the future role of bevacizumab (Avastin) in the treatment of patients with early-stage colorectal cancer. Last month, it was announced that bevacizumab
A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies.
ORLANDO—Preliminary data suggested that Novartis’ RAD001 is moderately active in stabilizing the progression of HCC, according to a poster presentation at ASCO 2009 (abstract 4587). In this phase I trial, researchers in Taiwan enrolled 36 advanced HCC patients whose disease was not suitable for local therapy or had progressed after local therapy.
My organization, the National LGBT Cancer Network, estimates that there are one million lesbian, gay, bisexual, and transgender (LGBT) cancer survivors in the U.S. today. While you may not know it, you likely have LGBT cancer survivors in your community.
Recipients of the 2009 ASCO Special Awards have been announced. Clara D. Bloomfield, MD, (left) will be given the David A. Karnofsky Memorial Award; the Science of Oncology Award will go to Bert Vogelstein, MD; Olufunmilayo Olopade, MBBS, will receive the ASCO-American Cancer Society Award; the B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology will be given to Martine Extermann, MD, PhD; the Pediatric Oncology Award will be presented to William E. Evans, PharmD, and Mary V. Relling, PharmD; John H. Glick, MD, will take home the Distinguished Achievement Award; Diane S. Blum, MSW, is the recipient of Partners in Progress Award; Richard Pazdur, MD, will be given the Special Recognition Award.
Highly expensive imaging technologies are a lightning rod in today’s contentious healthcare landscape. Critics contend that imaging services are grossly overused, while supporters argue that proper use of imaging saves lives and reduces downstream cancer costs.
As comparative effectiveness research matures from a political buzz phrase to a decision-making process, leaders in the oncology community are concerned about the effect this latest government initiative might have on community practices that already feel overregulated.
A novel drug that targets an important protein receptor that supports B-cell lymphoma cells produced significant responses in non-Hodgkin’s lymphoma patients who had failed prior therapies. Results from the phase II trial of fostamatinib disodium in 68 heavily pretreated relapsed and refractory B-cell NHL patients revealed that the treatment has significant promise and should undergo further clinical testing, according to lead investigator Jonathan W. Friedberg, MD, of the James P. Wilmot Cancer Center at the University of Rochester in New York.